Atlas Venture Life Science Advisors, LLC
CIK: 0001917529Latest portfolio: $865.2M · Q4 2025
Holdings
8
Total Value
$865.2M
New Positions
1
Closed Positions
2
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 4,659,874 | $362.6M | 41.91% | -236,588 | |
| 2 | DYNDyne Therapeutics, Inc. | 9,130,465 | $178.6M | 20.64% | — | |
| 3 | SIONSionna Therapeutics, Inc. | 2,995,602 | $123.2M | 14.24% | -619,925 | |
| 4 | IRONDisc Medicine, Inc. | 1,513,875 | $120.2M | 13.90% | -628,742 | |
| 5 | DAWNDay One Biopharmaceuticals, Inc. | 6,412,560 | $59.8M | 6.91% | -17,697 | |
| 6 | KRROKorro Bio, Inc. | 1,137,149 | $9.1M | 1.05% | — | |
| 7 | QTTBQ32 Bio, Inc. | 2,092,106 | $6.9M | 0.80% | — | |
| 8 | GBIOGeneration Bio, Co. | 827,946 | $4.7M | 0.54% | NEW |
Quarterly Changes
Sector Breakdown
Healthcare100.0% ($3.6258417859112326e+31T)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 13, 2026 | $865.2M | 8 |
| Q3 2025 | Nov 13, 2025 | $752.6B | 9 |
| Q2 2025 | Aug 12, 2025 | $662.4B | 11 |
| Q1 2025 | May 14, 2025 | $521.8B | 13 |
| Q4 2024 | Feb 6, 2025 | $819.7B | 13 |
| Q3 2024 | Nov 13, 2024 | $1.1T | 14 |
| Q2 2024 | Aug 9, 2024 | $949.6B | 15 |
| Q1 2024 | May 6, 2024 | $1.1T | 16 |
| Q4 2023 | Feb 9, 2024 | $839.8B | 16 |
| Q3 2023 | Nov 13, 2023 | $645.6B | 15 |
| Q2 2023 | Aug 11, 2023 | $803.6B | 15 |
| Q1 2023 | May 15, 2023 | $738.6B | 16 |
| Q4 2022 | Feb 14, 2023 | $830.2B | 17 |
| Q3 2022 | Nov 9, 2022 | $906.2M | 17 |
| Q2 2022 | Aug 3, 2022 | $598.2M | 16 |
| Q1 2022 | May 16, 2022 | $791.0M | 17 |
| Q1 2022 | May 16, 2022 | $1.1B | 16 |
Fund Information
Atlas Venture Life Science Advisors, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $865.2M across 8 holdings. The largest position is Kymera Therapeutics, Inc. (KYMR), representing 41.9% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 2 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.